热门资讯> 正文
Gain Therapeutics Says Phase 1 Data Confirm Safety of Parkinson's Disease Drug Candidate
2024-08-29 20:48
08:48 AM EDT, 08/29/2024 (MT Newswires) -- Gain Therapeutics (GANX) said Thursday that a review of unblinded data from a phase 1 study of GT-02287 to treat Parkinson's disease confirmed that the drug candidate is safe and generally well tolerated.
The company said it expects to begin the phase 1b study in Q4 and present the results middle of next year.
Shares of Gain Therapeutics were down more than 5% in recent premarket activity.
Price: 1.2600, Change: -0.07, Percent Change: -5.26
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
